Taiwan Bispecific Antibody and Immuno-Oncology Companies
As of October 22, 2026, this table includes bispecific antibody, ADC or immunocytokine programs at 4 Taiwan companies. [1] [2] [3] [4] [5]
The selected OBI-201, TSY-310 and PD-1-IL-2v programs remain preclinical, while the overall AP203 study is registered as Phase 1/2. [1] [2] [3] [4]
| Company | Ticker | Product / pipeline | Indication | Latest verified stage | Stage source and date | Most recent catalyst |
|---|---|---|---|---|---|---|
| OBI Pharma Company source | 4174 | OBI-201 (TROP2 × HER2 bispecific ADC) | Solid tumors | Preclinical | 2026-10-22 Stage source OBI-201 | — |
| Formosa Pharmaceuticals Company source | 6838 | TSY-310 (EGFR × ROR1 bispecific ADC) | Solid tumors | Preclinical | 2026-09-02 Stage source TSY-310雙靶點奈米抗體ADC | — |
| PharmaEssentia Company source | 6446 | PD-1-IL-2v (bispecific immunocytokine) | Solid tumors | Preclinical; IND-enabling | 2026-10-22 Stage source IND ENABLING | The cited company presentation plans an IND for PD-1-IL-2v in 2026; submission is not verified. 2026-10-22 Source Planned IND in 2026 |
| AP Biosciences Company source | 6945 | AP203 (PD-L1 × CD137 bispecific antibody) Product source | Locally advanced or metastatic solid tumors | Phase 1/2 study; registered as recruiting | 2025-03-26 Stage source RECRUITING | — |
Scope and public-document limits
This is a source-verified selection rather than an industry census. Stages retain their individual source dates; undisclosed names, indications and event dates are not filled in.